The coronary collateral circulation is an alternative source of blood supply to the myocardium jeopardized by failure of the original vessel to provide adequate flow. Angiogenesis growth factors induce angiogenesis to promote collateral circulation, been demonstrated in a number of different animal test and phase Ⅰ clinical experience to induce collateralization in the ischemic area and improve cardiac function. Although there are several unsolved questions, the pharmacologic use of angiogenesis growth factors will represent a viable therapeutic alternative for the patients with ischemic heart disease.